Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
about
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsAntiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsUpdate on human herpesvirus 6 biology, clinical features, and therapyCMV: Prevention, Diagnosis and TherapyNon-nucleoside inhibitors of herpesviruses.Drugs and the retina.Spontaneous resolution of intravitreal steroid-induced bilateral cytomegalovirus retinitisAntimicrobial prophylaxis in solid-organ transplantation.Oral and dental aspects of chronic renal failure.A scalable approach to prevent teratoma formation of human embryonic stem cellsAcute Herpetic Keratitis: What is the Role for Ganciclovir Ophthalmic Gel?Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients.Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers).Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An OverviewDesign, Synthesis, and the Biological Evaluation of a New Series of Acyclic 1,2,3-Triazole Nucleosides.The absence of p53 during Human Cytomegalovirus infection leads to decreased UL53 expression, disrupting UL50 localization to the inner nuclear membrane, and thereby inhibiting capsid nuclear egress.Effects of four nucleoside analogues used as antiviral agents on rat Sertoli cells (SerW3) in vitro.Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Effect of duration and intensity of ganciclovir exposure on lymphoblastoid cell toxicity.Treatment of Cytomegalovirus Infection with Cidofovir and CMV Immune Globulin in a Lung Transplant Recipient.Phosphonylated Acyclic Guanosine Analogues with the 1,2,3-Triazole Linker.Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID miceA pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection.Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children.(Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation.Rapid detection and quantitation of ganciclovir resistance in cytomegalovirus quasispecies.
P2860
Q24200697-08F5E7E7-4052-461C-8793-07EA5591638CQ24243124-34D98E45-6D03-426F-A848-97A47E1C0A65Q24557543-DBB59080-255D-428D-AECB-600887296754Q26824869-104E3156-EBD1-4D24-89EA-EB9C57C56DF2Q34622466-EA4F62FD-2D52-4E13-92D2-F3FBB4024ECAQ35779346-E9AE6D8D-F0EC-45DD-BF76-3C54A385AD65Q35886969-308BE0C3-EB75-4937-904D-18175B1FAD11Q35917546-C8E9D714-EE51-4999-B329-3313F4943175Q36050817-1F8316F4-AD64-4966-923F-B9F7260E6B7EQ36294776-62F68F18-47FA-47B9-A3E9-1547CB5FF317Q36748051-1EA714A7-149B-43B0-A4DD-01182700BE51Q37276889-D9D8C0BC-CD46-48DC-AD59-786DB0F85DD5Q37409907-3DCC4CB2-1D18-4694-A6EA-510E824F3F65Q37544453-0745B0A4-4530-49C2-979A-1670020BE338Q37724248-27195822-88B2-4734-98EE-D58127D3F794Q37858520-BF9D7E30-8E68-43E6-B8A2-A017E7CAECA2Q38599972-7C8FA28E-CD75-499D-9768-19F57660D558Q38695987-7D7C8EB2-FAFD-4956-8DC9-19C726DF9A21Q38753361-67F09D68-1246-401C-83E3-FDE9CC083B0EQ38768476-51FA5324-D99C-4894-874F-267DB1B8EFB7Q38875887-29E1B312-9079-4ECC-9AEE-C2B9ED99B22BQ39819129-850FCBAE-2133-4580-9D0A-1952CCACBFF3Q40788353-487CF7FF-BC83-486D-9F54-18871F47D04EQ41186604-18160732-C432-4D86-9D8D-5412A2F8350BQ41818018-71594F34-F504-46DC-9EAD-7F002A583605Q41897266-CA081D5D-F4BC-480B-AF36-47890C60E338Q44781273-98CD1C92-FFBB-4AB6-8FA1-E3285AB771F0Q45358050-8C787C43-84F0-4E2D-AAF6-101CF6A92557Q48039802-1CD34672-F5B8-411C-A24B-D883DE3EA7E4
P2860
Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Ganciclovir: an update of its ...... ease in transplant recipients.
@ast
Ganciclovir: an update of its ...... ease in transplant recipients.
@en
Ganciclovir: an update of its ...... ease in transplant recipients.
@nl
type
label
Ganciclovir: an update of its ...... ease in transplant recipients.
@ast
Ganciclovir: an update of its ...... ease in transplant recipients.
@en
Ganciclovir: an update of its ...... ease in transplant recipients.
@nl
prefLabel
Ganciclovir: an update of its ...... ease in transplant recipients.
@ast
Ganciclovir: an update of its ...... ease in transplant recipients.
@en
Ganciclovir: an update of its ...... ease in transplant recipients.
@nl
P1433
P1476
Ganciclovir: an update of its ...... ease in transplant recipients.
@en
P2093
P304
P356
10.2165/00003495-200161080-00016
P577
2001-01-01T00:00:00Z
P6179
1004508061